Glenmark Life Sciences posts Q2 FY25 net profit at Rs. 95.31 Cr

Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024

Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024

Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr

Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024

Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr

Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Zydus receives acceptability from WHO for Typhoid Vi Conjugate Vaccine ZyVac TCV

Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations

He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024